Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
Philip Hampton,1 Emma Borg,2 Jes Birger Hansen,2 Matthias Augustin3 1Department of Dermatology, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; 2LEO Pharma A/S, Ballerup, Denmark; 3Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Cen...
Enregistré dans:
Auteurs principaux: | Hampton P, Borg E, Hansen JB, Augustin M |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/305c7a0ed75d4f8ca264b55011c7cced |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
par: Chan Y, et autres
Publié: (2021) -
Ustekinumab in the therapy of chronic plaque psoriasis
par: Jenna L O’Neill, et autres
Publié: (2009) -
Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
par: Aline Lissa Okita, et autres
Publié: (2020) -
Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
par: Annunziata Dattola, et autres
Publié: (2021) -
Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
par: Matsumoto S, et autres
Publié: (2018)